Literature DB >> 22289993

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.

J A Woyach, G Lozanski, A S Ruppert, A Lozanski, K A Blum, J A Jones, J M Flynn, A J Johnson, M R Grever, N A Heerema, J C Byrd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22289993      PMCID： PMC3675648          DOI： 10.1038/leu.2011.375

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Authors:  John C Byrd; John G Gribben; Bercedis L Peterson; Michael R Grever; Gerard Lozanski; David M Lucas; Ben Lampson; Richard A Larson; Michael A Caligiuri; Nyla A Heerema
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

2.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

Authors:  H Döhner; K Fischer; M Bentz; K Hansen; A Benner; G Cabot; D Diehl; R Schlenk; J Coy; S Stilgenbauer
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

3.  Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival.

Authors:  J R Neilson; R Auer; D White; N Bienz; J J Waters; J A Whittaker; D W Milligan; C D Fegan
Journal:  Leukemia       Date:  1997-11       Impact factor: 11.528

4.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

5.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

Authors:  Rong Chen; Michael J Keating; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

6.  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Thomas E Witzig; Stephanie R Fink; Robert B Jenkins; Sarah F Paternoster; Stephanie A Smoley; Kimberly J Stockero; Danielle M Nast; Heather C Flynn; Renee C Tschumper; Susan Geyer; Clive S Zent; Tim G Call; Diane F Jelinek; Neil E Kay; Gordon W Dewald
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

Authors:  John C Byrd; Thomas S Lin; James T Dalton; Di Wu; Mitch A Phelps; Beth Fischer; Mollie Moran; Kristie A Blum; Brad Rovin; Michelle Brooker-McEldowney; Sarah Broering; Larry J Schaaf; Amy J Johnson; David M Lucas; Nyla A Heerema; Gerard Lozanski; Donn C Young; Jose-Ramon Suarez; A Dimitrios Colevas; Michael R Grever
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

8.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

9.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

Authors:  E Wattel; C Preudhomme; B Hecquet; M Vanrumbeke; B Quesnel; I Dervite; P Morel; P Fenaux
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

10.  Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma.

Authors:  G Juliusson; K H Robèrt; A Ost; K Friberg; P Biberfeld; B Nilsson; L Zech; G Gahrton
Journal:  Blood       Date:  1985-01       Impact factor: 22.113
View more
  21 in total

1.  ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

Authors:  Emilia Mahoney; David M Lucas; Sneha V Gupta; Amy J Wagner; Sarah E M Herman; Lisa L Smith; Yuh-Ying Yeh; Leslie Andritsos; Jeffrey A Jones; Joseph M Flynn; Kristie A Blum; Xiaoli Zhang; Amy Lehman; Hui Kong; Metin Gurcan; Michael R Grever; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

Review 2.  Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?

Authors:  Fabienne McClanahan; John Gribben
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-26       Impact factor: 3.722

3.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Authors:  Philip A Thompson; Susan M O'Brien; William G Wierda; Alessandra Ferrajoli; Francesco Stingo; Susan C Smith; Jan A Burger; Zeev Estrov; Nitin Jain; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

4.  Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; Amy S Ruppert; Kami Maddocks; Leslie Andritsos; Robert Baiocchi; Jeffrey Jones; Amy J Johnson; Lisa L Smith; Yuan Zhao; Yonghua Ling; Junan Li; Mitch A Phelps; Michael R Grever; John C Byrd; Joseph M Flynn
Journal:  Leuk Res       Date:  2013-07-15       Impact factor: 3.156

Review 5.  Personalized medicine in CLL: current status and future perspectives.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; Michael J Keating; Zeev Estrov
Journal:  Cancer Lett       Date:  2013-07-20       Impact factor: 8.679

6.  Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.

Authors:  Samantha M Jaglowski; Amy S Ruppert; Nyla A Heerema; Anissa Bingman; Joseph M Flynn; Michael R Grever; Jeffrey A Jones; Patrick Elder; Steven M Devine; John C Byrd; Leslie A Andritsos
Journal:  Br J Haematol       Date:  2012-07-25       Impact factor: 6.998

Review 7.  Development of anticancer drugs based on the hallmarks of tumor cells.

Authors:  Natalia Bailón-Moscoso; Juan Carlos Romero-Benavides; Patricia Ostrosky-Wegman
Journal:  Tumour Biol       Date:  2014-01-29

8.  The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.

Authors:  A J Johnson; Y-Y Yeh; L L Smith; A J Wagner; J Hessler; S Gupta; J Flynn; J Jones; X Zhang; R Bannerji; M R Grever; J C Byrd
Journal:  Leukemia       Date:  2012-05-30       Impact factor: 11.528

Review 9.  What do we do with chronic lymphocytic leukemia with 17p deletion?

Authors:  L Sellner; S Denzinger; S Dietrich; H Glimm; O Merkel; P Dreger; T Zenz
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 10.  Prognostic Factors in the Era of Targeted Therapies in CLL.

Authors:  Prajwal Boddu; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.